Statins Linked to Lower Liver Cancer Risk but Higher Thyroid Cancer Risk in a 232,000-Person Korean Study
A Korean nationwide cohort of 232,133 people found statin use associated with roughly half the liver cancer risk — and a 19% higher thyroid cancer risk.
By Sanare Lab · October 1, 2026 · 2 min read
Key Takeaway
Statins — common cholesterol-lowering drugs — may affect cancer risk differently by organ. In a Korean study of 232,000+ adults, statin users had about half the liver cancer risk, but a 19% higher thyroid cancer risk. The study was observational (researchers watched rather than assigned treatments), so it shows links, not proof of cause.
The team used Korea's National Health Insurance Service database: 232,133 adults screened in 2009–2010 were followed until 2019 — 67,064 statin users (prescribed a statin for at least 6 months) versus 165,069 non-users. Cancer cases were counted per person-years — a standard way to account for how long each person was observed. Related reading: a preprint on statins and the immune response in ovarian cancer.
After adjusting for confounders (other factors that could skew the result), overall cancer risk was slightly lower in users — adjusted hazard ratio (aHR) 0.96, about 4% lower, a borderline result. Liver cancer was the standout: aHR 0.52, meaning the rate in users was roughly half that in non-users; its 95% confidence interval (0.44–0.61 — the range the true value most likely falls in) stayed well below 1. Related reading: survey data on statins in older cancer survivors.
The opposite pattern appeared for thyroid cancer: aHR 1.19 (95% CI 1.07–1.33), a 19% higher risk in users. The authors call for research into these organ-specific effects; being observational, the study proves neither direction. For context, see how statins may starve cancer cells of a key nutrient and protocols that already include a statin (atorvastatin); for dosing questions, our dosing calculator.
In plain words
What happened: Researchers compared health records of 232,000+ Korean adults over about a decade: people who took statins (cholesterol pills) versus people who did not.
Why it matters: Statins block a pathway cells use to make cholesterol — one some cancers also rely on. The effect on cancer risk differed by organ: liver and thyroid moved in opposite directions.
How strong is the evidence: A large observational study — real life watched, not an experiment. It shows links, not proof; other differences between the groups may play a role.
What it means for you: Nothing changes today — do not start or stop a statin over this study; these drugs protect the heart, and that decision belongs with your doctor. Worried about the thyroid finding? Raise it at your next check-up.
References
- Seo EH, Moon J, Kim J, et al. Statin Use and Site-Specific Cancer Risk: A Nationwide Cohort Study Using Korean Health Insurance Data (a cohort study follows a group of people over time). Journal of Lipid and Atherosclerosis. 2026 Sep. doi:10.12997/jla.2026.15.3.498. PMID: 42812693.
Medical Disclaimer
This article is for informational purposes only and is not medical advice. The study was observational and shows associations, not proof of cause. Never start, stop or change any medication or supplement without consulting a licensed healthcare provider.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.